Come and join our meetup on Monday 18 September to talk about access to SMA treatments and what we all need to do to receive it.
Government will not pay for such an expensive treatment unless we act!
We are meeting at Amba Hotel Charing Cross, Strand, London WC2N 5HX from 12pm to 3pm.
Children are welcome, but no care can be provided. No coughing or sneezing kids please!
– The TreatSMA Team
Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.
SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…
This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.
